Search Results - subject:"PHARMACEUTICAL COMPANIES"

Investigation on the Effects of Elimination of Waste Levels in Managing Cost Levels In the Pharmaceutical Industry in Kenya

Ouma, Antony Muse; Njeru, Agnes W.; Dennis, Juma - In: International Journal of Academic Research in Business … 4 (2014) 10, pp. 361-368

16th Edition, 2001 & The Kenya Telephone Directory 2004 and nine pharmaceutical companies, 23 employees in manufacturing … pharmaceutical companies in Kenya should fully adopt lean manufacturing in order to manage its cost levels hence give the firm a …

Persistent link: https://www.econbiz.de/10011084882

Impact of Corporate Social Responsibility on OTC Medicines Consumers

Roblek, Vasja; Bertoncelj, Andrej - In: The AMFITEATRU ECONOMIC journal 16 (2014) 35, pp. 12-12

In the article is presented the case of trust-based marketing of over-the-counter (OTC) medicines. The relationship between the hypotheses was tested by means of structural equation modelling. The results of the first model show that the predictor variable (consumer satisfaction with safety and...

Persistent link: https://www.econbiz.de/10010819074

A CONTENT ANALYSIS OF THE MISSION STATEMENTS OF IRAN, TURKEY, INDIA AND UNITED STATES PHARMACEUTICAL COMPANIES

AZIZI, Shahriar; HOSSEINABADI, Vahid - In: Management and Marketing Journal XII (2014) 1, pp. 52-66

Pharmaceutical companies play a critical role in healthcare economy. Articulating mission statement of a Pharmaceutical …, Indian and American pharmaceutical companies are analyzed. By using content analysis, frequencies of nine elements of the …/growth/profitability, philosophy, self-perception, public image and employee were investigated. 98 mission statements of pharmaceutical companies (32 …

Persistent link: https://www.econbiz.de/10010936640

Sustaining Universal Health Coverage in France: A Perpetual Challenge

Barroy, Helene; Or, Zeynep; Kumar, Ankit; Bernstein, David - Economics Research, World Bank Group - 2014

While universal health coverage (UHC) offers a powerful goal for a nation, all countries-irrespective of income are struggling with achieving or sustaining UHC. France is a high-income country where HC is in effect universal. Health-related costs are covered by a mix of mandatory social health...

Persistent link: https://www.econbiz.de/10010937833

When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity-Working Paper 334

Kremer, Michael; Snyder, Christopher M. - 2013

We argue that in pharmaceutical markets, variation in the arrival time of consumer heterogeneity creates differences between a producer’s ability to extract consumer surplus with preventives and treatments, potentially distorting R&D decisions. If consumers vary only in disease risk, revenue...

Persistent link: https://www.econbiz.de/10010729168

Sales promotion strategies of pharmaceutical companies : a perspective of qualification of medical representatives

Shah, Girish; Dubey, Rishi - In: GITAM journal of management : a quarterly publication … 16 (2018) 3, pp. 105-116

Persistent link: https://www.econbiz.de/10012049387

The extent of disclosure for corporate social responsibility in the financial reports of Jordanian pharmaceutical companies

Bataineh, Ashraf; Al-Karasneh, Huthaifa; Aldaibat, Bassam - In: International journal of financial research 9 (2018) 4, pp. 88-96

Persistent link: https://www.econbiz.de/10012237147

How behavioral finance patterns affect investors' activity in capital markets?

Rothman, Tiran - In: Inventi impact: emerging economies (2018) 1, pp. 23-27

Persistent link: https://www.econbiz.de/10012241606

Benefits of customer service in time of declining sales : the case of a Lebanese pharmaceutical company

Abou Hamad, Jennifer; Beyrouthy, Ghassan; Azzam, Mireille - In: Inventi impact: retailing & consumer services (2018) 3, pp. 164-177

Persistent link: https://www.econbiz.de/10012130286

Which form of venture capital is most supportive of innovation?

Bertoni, Fabio; Tykvová, Tereza - 2012

structure (syndicated vs. non-syndicated) moderate this impact. Using a sample of 865 young biotech and pharmaceutical companies …

Persistent link: https://www.econbiz.de/10010308273